| Exploring the role of cancer stem cells in radioresistance M Baumann, M Krause, R Hill Nature Reviews Cancer 8 (7), 545-554, 2008 | 965 | 2008 |
| Radiation oncology in the era of precision medicine M Baumann, M Krause, J Overgaard, J Debus, SM Bentzen, J Daartz, ... Nature Reviews Cancer 16 (4), 234-249, 2016 | 854 | 2016 |
| ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer BV Offersen, LJ Boersma, C Kirkove, S Hol, MC Aznar, AB Sola, ... Radiotherapy and oncology 114 (1), 3-10, 2015 | 595 | 2015 |
| Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments M Krause, A Dubrovska, A Linge, M Baumann Advanced drug delivery reviews 109, 63-73, 2017 | 329 | 2017 |
| Human gastric cancer modelling using organoids T Seidlitz, SR Merker, A Rothe, F Zakrzewski, C von Neubeck, ... Gut 68 (2), 207-217, 2019 | 294 | 2019 |
| Aldehyde dehydrogenase is regulated by β-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells M Cojoc, C Peitzsch, I Kurth, F Trautmann, LA Kunz-Schughart, ... Cancer research 75 (7), 1482-1494, 2015 | 267 | 2015 |
| Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results M Baumann, M Krause Radiotherapy and oncology 72 (3), 257-266, 2004 | 240 | 2004 |
| β1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy I Eke, Y Deuse, S Hehlgans, K Gurtner, M Krause, M Baumann, ... The Journal of clinical investigation 122 (4), 1529-1540, 2012 | 235 | 2012 |
| CD 8+ tumour‐infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre … P Balermpas, F Rödel, C Rödel, M Krause, A Linge, F Lohaus, ... International journal of cancer 138 (1), 171-181, 2016 | 234 | 2016 |
| A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling S Leger, A Zwanenburg, K Pilz, F Lohaus, A Linge, K Zöphel, J Kotzerke, ... Scientific reports 7 (1), 13206, 2017 | 231 | 2017 |
| ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1 BV Offersen, LJ Boersma, C Kirkove, S Hol, MC Aznar, AB Sola, ... Radiotherapy and oncology: journal of the European Society for Therapeutic …, 2016 | 224 | 2016 |
| Three-dimensional cell growth confers radioresistance by chromatin density modification K Storch, I Eke, K Borgmann, M Krause, C Richter, K Becker, E Schröck, ... Cancer research 70 (10), 3925-3934, 2010 | 221 | 2010 |
| EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms M Baumann, M Krause, E Dikomey, K Dittmann, W Dörr, U Kasten-Pisula, ... Radiotherapy and Oncology 83 (3), 238-248, 2007 | 213 | 2007 |
| Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial BV Offersen, J Alsner, HM Nielsen, EH Jakobsen, MH Nielsen, M Krause, ... Journal of Clinical Oncology 38 (31), 3615-3625, 2020 | 212 | 2020 |
| European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for … I Meattini, C Becherini, L Boersma, O Kaidar-Person, GN Marta, ... The Lancet Oncology 23 (1), e21-e31, 2022 | 178 | 2022 |
| Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation A Yaromina, M Krause, H Thames, A Rosner, M Krause, F Hessel, ... Radiotherapy and oncology 83 (3), 304-310, 2007 | 175 | 2007 |
| HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a … F Lohaus, A Linge, I Tinhofer, V Budach, E Gkika, M Stuschke, ... Radiotherapy and oncology 113 (3), 317-323, 2014 | 166 | 2014 |
| Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell … M Baumann, T Herrmann, R Koch, W Matthiessen, S Appold, B Wahlers, ... Radiotherapy and Oncology 100 (1), 76-85, 2011 | 166 | 2011 |
| Relative biological effectiveness in proton beam therapy–Current knowledge and future challenges A Lühr, C von Neubeck, M Krause, EGC Troost Clinical and translational radiation oncology 9, 35-41, 2018 | 156 | 2018 |
| HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary … A Linge, F Lohaus, S Löck, A Nowak, V Gudziol, C Valentini, ... Radiotherapy and Oncology 121 (3), 364-373, 2016 | 156 | 2016 |
Daniel ZipsRadiation Oncology Charite BerlinVerified email at charite.de
